Skip to main content

Advertisement

SpringerLink
Log in

Peyronie’s Disease: A Review of Etiology, Diagnosis, and Management

  • Male Sexual Dysfunction and Disorders (SE Althof and AW Pastuszak, Section Editors)
  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript

Abstract

Peyronie’s disease (PD) is a superficial fibrosing disorder of the penis resulting in plaque formation and penile deformity. Once considered rare, PD has more recently been found in up to 13 % of men, and can negatively affect sexual and psychosocial function of both patients and their partners. While the etiology of PD is unclear, it is thought to result from an inciting traumatic event followed by aberrant fibrosis or dysregulated wound healing. The evaluation of men presenting with PD includes a detailed history and physical examination, focusing on the penis in both the flaccid and erect states. PD is often associated with erectile dysfunction (ED), as well as several other comorbidities. Laboratory testing is not needed to diagnose PD, although given the associations between PD and systemic diseases including hypogonadism, diabetes, and cardiovascular disease, screening and workup for these conditions in men with PD may be warranted. Treatment modalities for PD are diverse and include oral, topical, intralesional, mechanical, and surgical therapies. Oral, topical, and mechanical therapies generally have little evidence supporting their efficacy. Several intralesional therapies, including interferon α2b and collagenase Clostridium histolyticum, have demonstrated efficacy in the treatment of PD. Surgical treatment, indicated in men with significant, stable deformity, includes plication of the tunica albuginea, plaque incision/excision and grafting, and placement of inflatable penile prosthesis (IPP) with or without additional maneuvers to achieve desired results, and has high success rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. El-Sakka AI. Prevalence of Peyronie’s disease among patients with erectile dysfunction. Eur Urol. 2006;49(3):564–9.

    PubMed  Google Scholar 

  2. Kadioglu A, Sanli O, Akman T, et al. Factors affecting the degree of penile deformity in Peyronie disease: an analysis of 1001 patients. J Androl. 2011;32(5):502–8.

    PubMed  Google Scholar 

  3. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146(4):1007–9.

    CAS  PubMed  Google Scholar 

  4. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88(7):727–30.

    CAS  PubMed  Google Scholar 

  5. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.

    PubMed Central  PubMed  Google Scholar 

  6. de la Peyronie F. Sur Quelques Obstacles Qui S’opposent a L’ejaculation Naturelle de la Semence. Mem Acad Chir. 1743;1.

  7. Borgogni T. Cyrugia edita et compilata. Venice1498 (written 1265–1275).

  8. Akkus E. Historical review of Peyronie’s disease: de la Peyronie to Devine. In: Levine LA, editor. Peyronie’s disease: a guide to clinical management. Totowa, NJ: Humana Press; 2007. p. 1–8.

    Google Scholar 

  9. Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 Pt 1):2350–3.

    PubMed  Google Scholar 

  10. Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sexual Med. 2010;7(3):1254–61.

    Google Scholar 

  11. Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19(2):213–7.

    CAS  PubMed  Google Scholar 

  12. Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med. 2008;5(8):1985–90. Important work that emphasizes the significant impact that PD has on a man’s mental and psychosocial well-being and the need for a multidisciplinary approach to treatment.

    PubMed  Google Scholar 

  13. Nelson CJ, Mulhall JP. Psychological impact of Peyronie’s disease: a review. J Sex Med. 2013;10(3):653–60.

    PubMed  Google Scholar 

  14. Hartzell R. Psychosexual symptoms and treatment of Peyronie’s disease within a collaborative care model. Sex Med. 2014;2(4):168–77.

    PubMed Central  PubMed  Google Scholar 

  15. Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190(2):627–34. Describes the first quality of life questionnaire validated for use specifically in PD.

    PubMed  Google Scholar 

  16. Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie’s disease: a case–control study. BJU Int. 2006;97(3):570–4.

    PubMed  Google Scholar 

  17. Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case–control study on risk factors for Peyronie’s disease. J Clin Epidemiol. 1998;51(6):511–5.

    CAS  PubMed  Google Scholar 

  18. La Pera G, Pescatori ES, Calabrese M, et al. Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50–69 years. Eur Urol. 2001;40(5):525–30.

    PubMed  Google Scholar 

  19. Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie’s disease: pilot data suggesting a significant relationship. J sex Med. 2009;6(6):1729–35.

    CAS  PubMed  Google Scholar 

  20. Nam HJ, Park HJ, Park NC. Does testosterone deficiency exaggerate the clinical symptoms of Peyronie’s disease? Int J Urol: off J Jpn Urol Assoc. 2011;18(11):796–800.

    CAS  Google Scholar 

  21. Kirby EW, Verges D, Matthews J, Carson CC, Coward RM. Low testosterone has a similar prevalence among men with sexual dysfunction due to either Peyronie’s disease or erectile dysfunction and does not correlate with Peyronie’s Disease severity. J Sex Med. 2015;12(3):690–6.

    CAS  PubMed  Google Scholar 

  22. Karavitakis M, Komninos C, Simaioforidis V, et al. The relationship between androgens, regulators of collagen metabolism, and Peyronie’s disease: a case control study. J Sex Med. 2010;7(12):4011–7.

    CAS  PubMed  Google Scholar 

  23. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175(6):2115–8. discussion 2118. Provides an excellent account of the natural history of PD, debunking the misconception of spontaneous resolution being common.

    PubMed  Google Scholar 

  24. Azadzoi KM, Schulman RN, Aviram M, Siroky MB. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. J Urol. 2005;174(1):386–93.

    CAS  PubMed  Google Scholar 

  25. Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction: potential future treatments. Endocrine. 2004;23(2–3):167–76.

    CAS  PubMed  Google Scholar 

  26. Ferrini MG, Kovanecz I, Sanchez S, et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007;76(5):915–23.

    CAS  PubMed  Google Scholar 

  27. Levine LA. Preface. In: Levine LA, editor. Peyronie’s disease: a guide to clinical management. Totowa, NJ: Humana Press; 2007. p. vi–ix.

    Google Scholar 

  28. Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol. 1997;157(1):276–81.

    CAS  PubMed  Google Scholar 

  29. Davis Jr CJ. The microscopic pathology of Peyronie’s disease. J Urol. 1997;157(1):282–4.

    PubMed  Google Scholar 

  30. El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF. Histological and ultrastructural alterations in an animal model of Peyronie’s disease. Br J Urol. 1998;81(3):445–52.

    CAS  PubMed  Google Scholar 

  31. Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease plaque. J Urol. 1997;157(1):311–5.

    CAS  PubMed  Google Scholar 

  32. Devine Jr CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol. 1997;157(1):285–90.

    PubMed  Google Scholar 

  33. Diegelmann RF. Cellular and biochemical aspects of normal and abnormal wound healing: an overview. J Urol. 1997;157(1):298–302.

    CAS  PubMed  Google Scholar 

  34. Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie’s disease: a review. J Urol. 2003;169(4):1234–41.

    PubMed  Google Scholar 

  35. Jalkut M, Gonzalez-Cadavid N, Rajfer J. New discoveries in the basic science understanding of Peyronie’s disease. Curr Urol Rep. 2004;5(6):478–84.

    PubMed  Google Scholar 

  36. Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast growth factor expression in Peyronie’s disease. J Urol. 2001;165(2):419–23.

    CAS  PubMed  Google Scholar 

  37. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nature clinical practice. Urology. 2005;2(6):291–7.

    CAS  PubMed  Google Scholar 

  38. Gonzalez-Cadavid NF, Rajfer J. Experimental models of Peyronie’s disease. Implications for new therapies. J Sex Med. 2009;6(2):303–13.

    CAS  PubMed  Google Scholar 

  39. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997;158(6):2284–90.

    CAS  PubMed  Google Scholar 

  40. Vernet D, Nolazco G, Cantini L, et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for Peyronie disease. Biol Reprod. 2005;73(6):1199–210.

    CAS  PubMed  Google Scholar 

  41. Vernet D, Ferrini MG, Valente EG, et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric oxide : Biol Chem / Off J Nitric Oxide Soc. 2002;7(4):262–76.

    CAS  Google Scholar 

  42. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int. 2003;91(9):830–8.

    CAS  PubMed  Google Scholar 

  43. El-Sakka AI, Selph CA, Yen TS, Dahiya R, Lue TF. The effect of surgical trauma on rat tunica albuginea. J Urol. 1998;159(5):1700–7.

    CAS  PubMed  Google Scholar 

  44. Willscher MK, Cwazka WF, Novicki DE. The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease. J Urol. 1979;122(1):34–5.

    CAS  PubMed  Google Scholar 

  45. Rompel R, Weidner W, Mueller-Eckhardt G. HLA association of idiopathic Peyronie’s disease: an indication of autoimmune phenomena in etiopathogenesis? Tissue Antigens. 1991;38(3):104–6.

    CAS  PubMed  Google Scholar 

  46. Nachtsheim DA, Rearden A. Peyronie’s disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol. 1996;156(4):1330–4.

    CAS  PubMed  Google Scholar 

  47. Nyberg Jr LM, Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol. 1982;128(1):48–51.

    PubMed  Google Scholar 

  48. Hauck EW, Hauptmann A, Weidner W, Bein G, Hackstein H. Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie’s disease. J Urol. 2003;170(4 Pt 1):1443–6.

    CAS  PubMed  Google Scholar 

  49. Leffell MS, Devine Jr CJ, Horton CE, et al. Non-association of Peyronie’s disease with HLA B7 cross-reactive antigens. J Urol. 1982;127(6):1223–4.

    CAS  PubMed  Google Scholar 

  50. Noss MB, Day NS, Christ GJ, Melman A. The genetics and immunology of Peyronie’s disease. Int J Impot Res. 2000;12 Suppl 4:S127–32.

    PubMed  Google Scholar 

  51. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology. 2004;64(2):399–404. Provides evidence that PD and DD may share a common pathophysiology.

    CAS  PubMed  Google Scholar 

  52. Casalone R, Mazzola D, Meroni E, et al. Cytogenetic and interphase cytogenetic analyses reveal chromosome instability but no clonal trisomy 8 in Dupuytren contracture. Cancer Genet Cytogenet. 1997;99(1):73–6.

    CAS  PubMed  Google Scholar 

  53. Dal Cin P, De Smet L, Sciot R, Van Damme B, Van den Berghe H. Trisomy 7 and trisomy 8 in dividing and non-dividing tumor cells in Dupuytren’s disease. Cancer Genet Cytogenet. 1999;108(2):137–40.

    CAS  PubMed  Google Scholar 

  54. Mulhall JP, Nicholson B, Pierpaoli S, Lubrano T, Shankey TV. Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie’s disease. Int J Impot Res. 2004;16(3):288–93.

    CAS  PubMed  Google Scholar 

  55. Mulhall JP, Martin DJ, Lubrano T, et al. Peyronie’s disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int J Impot Res. 2004;16(2):99–104. Reveals a link between PD and malignancy, which warrants further investigation.

    CAS  PubMed  Google Scholar 

  56. Zyluk A, Paszkowska-Szczur K, Gupta S, Scott RJ, Lubinski J, Debniak T. Dupuytren’s disease and the risk of malignant neoplasms. Hereditary Cancer Clin Pract. 2014;12(1):6.

    Google Scholar 

  57. Xiong T, Yang J, Wang H, et al. The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer. Mol Biol Rep. 2014;41(4):2629–34.

    CAS  PubMed  Google Scholar 

  58. Gao W, Romkes M, Zhong S, et al. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep. 2010;24(1):257–62.

    PubMed Central  CAS  PubMed  Google Scholar 

  59. Sobti RC, Kaur S, Sharma VL, Singh SK, Hosseini SA, Kler R. Susceptibility of XPD and RAD51 genetic variants to carcinoma of urinary bladder in North Indian population. DNA Cell Biol. 2012;31(2):199–210.

    PubMed Central  CAS  PubMed  Google Scholar 

  60. Williams JL, Thomas GG. The natural history of Peyronie’s disease. J Urol. 1970;103(1):75–6.

    CAS  PubMed  Google Scholar 

  61. Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol. 1990;144(6):1376–9.

    CAS  PubMed  Google Scholar 

  62. Berookhim BM, Choi J, Alex B, Mulhall JP. Deformity stabilization and improvement in men with untreated Peyronie’s disease. BJU Int. 2014;113(1):133–6.

    PubMed  Google Scholar 

  63. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie’s disease. J Urol. 2002;168(3):1075–9.

    PubMed  Google Scholar 

  64. Jordan GHM, K. A. Peyronie’s disease. In: Kavoussi LRNACPCAWAJ, ed. Campbell-Walsh Urology. Vol 1. 10 ed. Philadelphia: Elsevier Saunders; 2012:792–809.

  65. Wilson SKaC, C. C. Surgical straightening with penile prosthesis. In: Levine LA, ed. Peyronie’s disease: a guide to clinical management. Totowa, NJ: Humana Press; 2007:249–258.

  66. Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol. 2006;175(1):238–41. Provides important outcomes data for tunical plication and also provides evidence that patients’ description of their own deformity is inaccurate, supporting objective measurement of deformity on erect penile exam.

    PubMed  Google Scholar 

  67. Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie’s disease patients: comparison of three methods. J Sex Med. 2007;4(1):199–203.

    PubMed  Google Scholar 

  68. Pastuszak AJ. Current diagnosis and management of erectile dysfunction. Curr Sex Health Rep. 2014;6(3):164–76.

    PubMed Central  PubMed  Google Scholar 

  69. Mirone V. Combination nonsurgical therapy. In: Levine LA, editor. Peyronie’s disease: a guide to clinical management. Totowa, NJ: Humana Press; 2007. p. 111–9.

    Google Scholar 

  70. Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22(5):298–309.

    CAS  PubMed  Google Scholar 

  71. Husain J, Lynn NN, Jones DK, Collins GN, O’Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie’s disease: initial experience. BJU Int. 2000;86(4):466–8.

    CAS  PubMed  Google Scholar 

  72. Ballerini M, Baronzio GF, Capit, et al. Androtherm application for the Peyronie’s disease. Conf Papers in Med. 2013;2013:6.

    Google Scholar 

  73. Bystrom J. Induration penis plastica. Experience of treatment with procarbazine Natulan. Scand J Urol Nephrol. 1976;10(1):21–5.

    CAS  PubMed  Google Scholar 

  74. Morgan RJ, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie’s disease. Br J Urol. 1978;50(2):111–3.

    CAS  PubMed  Google Scholar 

  75. Oosterlinck W, Renders G. Treatment of Peyronie’s disease with procarbazine. Br J Urol. 1975;47(2):219–20.

    CAS  PubMed  Google Scholar 

  76. Claro JA, Passerotti CC, Figueiredo Neto AC, Nardozza Jr A, Ortiz V, Srougi M. An alternative non-invasive treatment for Peyronie’s disease. Int Braz J Urol : Off J Braz Soc Urol. 2004;30(3):199–204. discussion 204.

    Google Scholar 

  77. Hashimoto K, Hisasue S, Kato R, Kobayashi K, Shimizu T, Tsukamoto T. Outcome analysis for conservative management of Peyronie’s disease. Int J Urol : Off J Jpn Urol Assoc. 2006;13(3):244–7.

    Google Scholar 

  78. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology. 2006;67(5):1038–42.

    PubMed  Google Scholar 

  79. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4 Pt 1):1398–403. discussion 1403.

    CAS  PubMed  Google Scholar 

  80. Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie’s disease. Int J Impot Res. 1999;11(4):207–12.

    CAS  PubMed  Google Scholar 

  81. Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543–52. Summarizes the EAU guidelines for management of PD, which provided much-needed guidance that was previously lacking.

    PubMed  Google Scholar 

  82. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int. 2001;88(1):63–7.

    CAS  PubMed  Google Scholar 

  83. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie’s disease with tamoxifen. Br J Urol. 1992;70(6):648–51.

    CAS  PubMed  Google Scholar 

  84. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol. 1999;162(6):2003–5.

    CAS  PubMed  Google Scholar 

  85. Safarinejad MR. Efficacy and safety of omega-3 for treatment of early-stage Peyronie’s disease: a prospective, randomized, double-blind placebo-controlled study. J Sex Med. 2009;6(6):1743–54.

    CAS  PubMed  Google Scholar 

  86. Trost LW, Gur S, Hellstrom WJ. Pharmacological management of Peyronie’s disease. Drugs. 2007;67(4):527–45.

    CAS  PubMed  Google Scholar 

  87. Shindel AW, Lin G, Ning H, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J sex Med. 2010;7(6):2077–85.

    PubMed Central  CAS  PubMed  Google Scholar 

  88. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric oxide : Biol Chem / Off J Nitric Oxide Soc. 2003;9(4):229–44.

    CAS  Google Scholar 

  89. Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nature clinical practice. Urology. 2006;3(2):111–5. quiz 116.

    PubMed  Google Scholar 

  90. Jordan GH, Carson CC, Lipshultz LI. Minimally invasive treatment of Peyronie’s disease: evidence-based progress. BJU Int. 2014;114(1):16–24.

    PubMed  Google Scholar 

  91. El-Sakka AI, Bakircioglu ME, Bhatnagar RS, Yen TS, Dahiya R, Lue TF. The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol. 1999;161(6):1980–3.

    CAS  PubMed  Google Scholar 

  92. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie’s disease? A pilot study. Urology. 1994;44(2):291–5.

    CAS  PubMed  Google Scholar 

  93. Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12(3):169–75.

    CAS  PubMed  Google Scholar 

  94. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16(3):238–43.

    CAS  PubMed  Google Scholar 

  95. Zarafonetis CJ, Horrax TM. Treatment of Peyronie’s disease with potassium para-aminobenzoate (POTABA). J Urol. 1959;81(6):770–2.

    CAS  PubMed  Google Scholar 

  96. Weidner W, Hauck EW, Schnitker J, Urologists PsDSGoAGoG. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530–5. discussion 535–536.

    CAS  PubMed  Google Scholar 

  97. Di Stasi SM, Giannantoni A, Capelli G, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. BJU Int. 2003;91(9):825–9.

    PubMed  Google Scholar 

  98. Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol. 2004;171(4):1605–8.

    PubMed  Google Scholar 

  99. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972–5.

    CAS  PubMed  Google Scholar 

  100. Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie’s disease. Andrology. 2013;1(1):129–32.

    CAS  PubMed  Google Scholar 

  101. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology. 2007;69(6):1181–4.

    PubMed  Google Scholar 

  102. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie’s disease. Urology. 2007;69(5):950–4.

    PubMed  Google Scholar 

  103. Chung E, Garcia F, Young LD, Solomon M, Brock GB. A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome. J Urol. 2013;189(1):380–4.

    CAS  PubMed  Google Scholar 

  104. Heidari M, Nejadi JR, Ghate A, Delfan B, Iran-Pour E. Evaluation of intralesional injection of verapamil in treatment of Peyronie’s disease. JPMA. J Pak Med Assoc. 2010;60(4):291–293.

  105. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168(2):621–5. discussion 625–626.

    CAS  PubMed  Google Scholar 

  106. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522–4.

    CAS  PubMed  Google Scholar 

  107. Moskovic DJ, Alex B, Choi JM, Nelson CJ, Mulhall JP. Defining predictors of response to intralesional verapamil injection therapy for Peyronie’s disease. BJU Int. 2011;108(9):1485–9.

    CAS  PubMed  Google Scholar 

  108. Perugia G, Liberti M, Vicini P, Colistro F, Gentile V. Role of hyperthermia in the treatment of Peyronie’s disease: a preliminary study. Int J Hyperthermia : Off J Eur Soc Hyperthermic Oncol, N Am Hyperthermia Group. 2005;21(4):367–74.

    CAS  Google Scholar 

  109. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620–6.

    CAS  PubMed  Google Scholar 

  110. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467–71.

    CAS  PubMed  Google Scholar 

  111. Paulis G, Brancato T, D’Ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120–8.

    CAS  PubMed  Google Scholar 

  112. Paulis G, Cavallini G, Brancato T, Alvaro R. Peironimev-Plus(R) in the treatment of chronic inflammation of tunica albuginea (Peyronie’s disease). Results of a controlled study. Inflamm Allergy Drug Targets. 2013;12(1):61–7.

    CAS  PubMed  Google Scholar 

  113. Fitch 3rd WP, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease—a placebo-controlled pilot study. J Sex Med. 2007;4(2):477–84.

    CAS  PubMed  Google Scholar 

  114. Lenk S, Schonberger B. Penile deviation—our therapeutic concept. Acta Chir Hung. 1994;34(1–2):189–94.

    CAS  PubMed  Google Scholar 

  115. Bartsch G, Menander-Huber KB, Huber W, Marberger H. Orgotein, a new drug for the treatment of Peyronie’s disease. Eur J Rheumatol Inflamm. 1981;4(2):250–9.

    CAS  PubMed  Google Scholar 

  116. Gustafson H, Johansson B, Edsmyr F. Peyronie’s disease: experience of local treatment with Orgotein. Eur Urol. 1981;7(6):346–8.

    CAS  PubMed  Google Scholar 

  117. Riedl CR, Plas E, Vorauer K, Vcelar B, Wagner A, Pfluger H. Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease. Eur Urol. 2001;40(3):343–8. discussion 348–349.

    CAS  PubMed  Google Scholar 

  118. Riedl CR, Sternig P, Galle G, et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005;48(4):656–61.

    CAS  PubMed  Google Scholar 

  119. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl. 1999;20(4):444–8.

    CAS  PubMed  Google Scholar 

  120. Astorga R, Cantero O, Contreras D, et al. Intralesional recombinant interferon alpha-2b in Peyronie’s disease. Arch Esp Urol. 2000;53(7):665–71.

    CAS  PubMed  Google Scholar 

  121. Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie’s disease with local interferon-alpha 2b. BJU Int. 2001;87(7):654–7.

    CAS  PubMed  Google Scholar 

  122. Dang G, Matern R, Bivalacqua TJ, Sikka S, Hellstrom WJ. Intralesional interferon-alpha-2B injections for the treatment of Peyronie’s disease. South Med J. 2004;97(1):42–6.

    PubMed  Google Scholar 

  123. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie’s disease: a pilot study. Br J Urol. 1997;79(1):40–2.

    CAS  PubMed  Google Scholar 

  124. Polat O, Gul O, Ozbey I, Ozdikici M, Bayraktar Y. Peyronie’s disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol. 1997;29(4):465–71.

    CAS  PubMed  Google Scholar 

  125. Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJ. Outcomes of intralesional interferon-alpha2B for the treatment of Peyronie disease. J Urol. 2013;190(6):2194–9.

    CAS  PubMed  Google Scholar 

  126. Wegner HE, Andresen R, Knipsel HH, Miller K. Treatment of Peyronie’s disease with local interferon-alpha 2b. Eur Urol. 1995;28(3):236–40.

    CAS  PubMed  Google Scholar 

  127. Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394–8.

    CAS  PubMed  Google Scholar 

  128. Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJ. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie’s disease. J Sex Med. 2005;2(5):709–15.

    CAS  PubMed  Google Scholar 

  129. Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie’s disease by subgroups: results from two large, double-blind, randomized, placebo-controlled, phase 3 studies. BJU international. 2015.

  130. Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207. Findings of the IMPRESS trial, demonstrating safety and efficacy of clostridial collagenase in PD. This biologic agent is the only FDA-approved medical treatment for PD.

    CAS  PubMed  Google Scholar 

  131. Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268–74.

    CAS  PubMed  Google Scholar 

  132. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol. 1993;149(1):56–8.

    CAS  PubMed  Google Scholar 

  133. Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248–58.

    PubMed  Google Scholar 

  134. Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106(9):1352–6.

    PubMed  Google Scholar 

  135. Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815–21.

    PubMed  Google Scholar 

  136. Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009;56(2):363–9.

    PubMed  Google Scholar 

  137. Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190–5.

    CAS  PubMed  Google Scholar 

  138. Gontero P, Di Marco M, Giubilei G, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med. 2009;6(2):558–66.

    PubMed  Google Scholar 

  139. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468–73.

    PubMed  Google Scholar 

  140. Raheem AA, Garaffa G, Raheem TA, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106(8):1178–80.

    PubMed  Google Scholar 

  141. Lue TF, El-Sakka AI. Lengthening shortened penis caused by Peyronie’s disease using circular venous grafting and daily stretching with a vacuum erection device. J Urol. 1999;161(4):1141–4.

    CAS  PubMed  Google Scholar 

  142. Kim JH, Carson 3rd CC. Development of Peyronie’s disease with the use of a vacuum constriction device. J Urol. 1993;149(5 Pt 2):1314–5.

    CAS  PubMed  Google Scholar 

  143. Hakim LS, Munarriz RM, Kulaksizoglu H, Nehra A, Udelson D, Goldstein I. Vacuum erection associated impotence and Peyronie’s disease. J Urol. 1996;155(2):534–5.

    CAS  PubMed  Google Scholar 

  144. Furlow WL, Swenson Jr HE, Lee RE. Peyronie’s disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol. 1975;114(1):69–71.

    CAS  PubMed  Google Scholar 

  145. Incrocci L, Hop WC, Slob AK. Current sexual functioning in 106 patients with Peyronie’s disease treated with radiotherapy 9 years earlier. Urology. 2000;56(6):1030–4.

    CAS  PubMed  Google Scholar 

  146. Niewald M, Wenzlawowicz KV, Fleckenstein J, Wisser L, Derouet H, Rube C. Results of radiotherapy for Peyronie’s disease. Int J Radiat Oncol Biol Phys. 2006;64(1):258–62.

    PubMed  Google Scholar 

  147. Adibi M, Hudak SJ, Morey AF. Penile plication without degloving enables effective correction of complex Peyronie’s deformities. Urology. 2012;79(4):831–5.

    PubMed  Google Scholar 

  148. Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J SexMed. 2008;5(9):2221–8. discussion 2229–2230.

    Google Scholar 

  149. Kadioglu A, Sanli O, Akman T, Cakan M, Erol B, Mamadov F. Surgical treatment of Peyronie’s disease: a single center experience with 145 patients. Eur Urol. 2008;53(2):432–9.

    PubMed  Google Scholar 

  150. Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie’s disease. J Sex Med. 2007;4(5):1500–8. Describes use of various grafts in plaque incision/excision for PD and reports outcomes.

    PubMed  Google Scholar 

  151. Mulhall J, Ahmed A, Anderson M. Penile prosthetic surgery for Peyronie’s disease: defining the need for intraoperative adjuvant maneuvers. J Sex Med. 2004;1(3):318–21. Describes IPP placement for the surgical management in the PD patient with ED unresponsive to medical therapy and describes how to decide whether adjuvant maneuvers are necessary, as well as how to perform them.

    PubMed  Google Scholar 

  152. Usta MF, Bivalacqua TJ, Sanabria J, Koksal IT, Moparty K, Hellstrom WJ. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie’s disease. Urology. 2003;62(1):105–9.

    PubMed  Google Scholar 

  153. Gelbard MK, Hayden B. Expanding contractures of the tunica albuginea due to Peyronie’s disease with temporalis fascia free grafts. J Urol. 1991;145(4):772–6.

    CAS  PubMed  Google Scholar 

  154. Cormio L, Zucchi A, Lorusso F, et al. Surgical treatment of Peyronie’s disease by plaque incision and grafting with buccal mucosa. Eur Urol. 2009;55(6):1469–75.

    PubMed  Google Scholar 

  155. Akkus E, Ozkara H, Alici B, et al. Incision and venous patch graft in the surgical treatment of penile curvature in Peyronie’s disease. Eur Urol. 2001;40(5):531–6. discussion 537.

    CAS  PubMed  Google Scholar 

  156. Yafi FA, Sangkum P, McCaslin IR, Hellstrom WJ. Strategies for penile prosthesis placement in Peyronie’s disease and corporal fibrosis. Curr Urol Rep. 2015;16(4):491.

    Google Scholar 

  157. Chung PH, Scott JF, Morey AF. High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie’s disease. J Sex Med. 2014;11(6):1593–8.

    PubMed  Google Scholar 

  158. Akman T, Tefekli A, Armagan A, et al. Decorin as a new treatment alternative in Peyronie’s disease: preliminary results in the rat model. Andrologia. 2013;45(2):101–6.

    CAS  PubMed  Google Scholar 

  159. Castiglione F, Hedlund P, Van der Aa F, et al. Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease. Eur Urol. 2013;63(3):551–60.

    PubMed Central  CAS  PubMed  Google Scholar 

  160. Gokce A, Abd Elmageed ZY, Lasker GF, et al. Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie’s disease. Andrology. 2014;2(2):244–51.

    CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Aylin N. Bilgutay declares no conflict of interest.

Alexander W. Pastuszak declares that he is a NIH Men’s Reproductive Health Research (MRHR) K12 scholar (HD073917) and a Urology Care Foundation Russell Scott, Jr., MD, Resident Research Award recipient.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Author information

Authors and Affiliations

  1. Scott Department of Urology, Baylor College of Medicine, 6624 Fannin St. Suite 1700, Houston, TX, 77030, USA

    Aylin N. Bilgutay & Alexander W. Pastuszak

  2. Center for Reproductive Medicine, Baylor College of Medicine, Houston, TX, USA

    Alexander W. Pastuszak

Authors
  1. Aylin N. Bilgutay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander W. Pastuszak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander W. Pastuszak.

Additional information

This article is part of the Topical Collection on Male Sexual Dysfunction and Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bilgutay, A.N., Pastuszak, A.W. Peyronie’s Disease: A Review of Etiology, Diagnosis, and Management. Curr Sex Health Rep 7, 117–131 (2015). https://doi.org/10.1007/s11930-015-0045-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11930-015-0045-y

Keywords

Search

Navigation